Testing nivolumab added to chemotherapy for children with mediastinal lymphoma
Tests adding nivolumab to chemotherapy in children with thymic large B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Key facts
- Where
- Moscow and Saint Petersburg, RussiaSee the 2 sites
- Phase
- Phase 1/2
Where in Russia
- Dmitry Rogachev National Research CenterMoscow, RussiaNo longer taking part
- Pavlov University, RM Gorbacheva Research InstituteSaint Petersburg, RussiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Petersburg State Pavlov Medical University
- Trial code
- NCT06871007
- Record updated
- 11 March 2025
- Original description
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphomaRead full original descriptionShow less
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
Inclusion: Age from 0 years to 17 years 11 months; Established on the basis of histological and immunohistochemical studies, the diagnosis of PMLBL (the presence of programmed death-ligand on tumor cells is not necessary); Lack of specific therapy for lymphoma; Signed informed consent.
Exclusion: Age >18; History of specific therapy for lymphomas; Drug intolerance.